Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Remdesivir

- PMLiVE

US CDC recommends updated COVID-19 vaccines for autumn/winter season

Pfizer/BioNTech and Moderna’s updated vaccines will be available in the coming days

- PMLiVE

FDA approves Pfizer/BioNTech and Moderna’s updated COVID-19 vaccines

The vaccines have both been adapted to target the currently circulating XBB.1.5 Omicron variant

- PMLiVE

MIT researchers design more powerful RNA vaccines for COVID-19

The new type of RNA vaccine was shown to produce a stronger immune response at a lower dose

- PMLiVE

NHS England winter flu and COVID-19 vaccine programmes start early

Those who are eligible will be offered a vaccination from 18 September 2023 onwards

- PMLiVE

Eli Lilly’s Mounjaro receives NICE recommendation to treat type 2 diabetes

Around 180,000 patients with type 2 diabetes could benefit from the new treatment option

- PMLiVE

NICE issues two recommendations for UCB’s inflammatory disease drug

Bimzelx is now recommended to treat certain patients with psoriatic arthritis and axial spondyloarthritis, two forms of chronic inflammatory arthritis

- PMLiVE

Tonix’s long COVID drug fails to meet mid-stage trial primary endpoint

TNX-102 SL was shown to effectively improve fatigue symptoms in people with long COVID

- PMLiVE

Moderna’s updated COVID-19 vaccine shows strong effect against BA.2.86 subvariant

The ‘highly mutated’ BA.2.86 subvariant is being closely monitored by global health authorities

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine approved by MHRA

The updated vaccine proved effective against the currently circulating XBB.1.5 subvariant

- PMLiVE

Bavarian Nordic’s COVID-19 booster ‘not suitable’ for emerging variants

Results showed that ABNCoV2 was not as effective against the circulating XBB.1.5 variant

- PMLiVE

New UK study suggests brain fog after COVID-19 is linked to blood clots

High levels of two proteins caused excess blood clotting in people with long COVID

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine approved by EC

The vaccine is approved for use in adults, children and infants over six months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links